Verimatrix Virtual Summit to Offer the Industry’s Latest Insights into Secure Video Delivery and Mobile Application Protection July 8-9
Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced its second virtual event this year designed to showcase how the global expansion of video, applications and connected devices has multiplied today’s attack surfaces. The Verimatrix Summer Summit consists of webcasts and private meetings taking place Wednesday, July 8, and Thursday, July 9, 2020.
“Now more than ever, organizations need to provide their customers with compelling experiences – but those experiences must be protected,” said Asaf Ashkenazi, COO of Verimatrix. “The Verimatrix Summer Summit will showcase why security matters more than ever -- and why in today’s modern connected world, security should be intuitive, user-friendly, and fast."
To kick off the Summit, Verimatrix Chairman and CEO Amedeo D’Angelo will underscore the importance of reliable and trustworthy security in the high-growth areas of video content, mobile applications and connected devices.
Verimatrix Virtual Summit Experience
Trusted Security: What it Means to Be a Trusted Security Partner
Wednesday, July 8, 6:30am PT / 1:30pm GMT
Amedeo D’Angelo, Chairman and CEO of Verimatrix, will explore what it means to be a trusted security partner, how the global expansion of video, applications and connected devices has multiplied today’s attack surfaces, and why the future of scalable, cost-effective SaaS security in the cloud is so exciting.
Every Second Counts: Building Better Sports Fan Experiences Through Secure Mobile Apps and Connected Game Play
Wednesday, July 8, 7:00am PT / 2:00pm GMT
Produced and moderated by SportsPro, this webinar will showcase how today’s technological change is forever altering fan perceptions and demands for the sporting experience. Franchises who provide trusted gameday ecosystems will win over the hearts, minds and pocketbooks of fans – while preserving valuable revenue streams. Panelists include Leanne Johnson, VP of Digital for the Milwaukee Bucks and Lucas von Cranach, CEO and Founder of Onefootball. Eoin Connolly, Editor-At-Large for SportsPro, will moderate.
Cloud Speed Ahead: Unlocking New Opportunities with Secure Content Distribution
Wednesday, July 8, 8:00am PT / 3:00pm GMT
Produced by Omdia, this webinar will explore how content providers are efficiently setting up new distribution channels around the world by maximizing novel OTT direct-to-consumer strategies without breaking the bank. Allen Tatara, Sr. Manager, Webinar Events at Omdia will moderate. Panelists will include Geoff Stedman, Enterprise Media Strategist at AWS Elemental, Asaf Askenazi, Chief Operating Officer at Verimatrix and Merrick Kingston, Associate Director at Omdia.
Apps Under Siege: Understanding Today’s Threats to Web/Mobile Applications and How to Defend Your IP While Safeguarding Customers
Wednesday, July 8, 11:30am PT / 6:30pm GMT
Experts from Jscrambler and Verimatrix will discuss how the lack of application protection is a giant blind spot and source of risk for many companies. Whether they want to acknowledge it or not, virtually every company today is in the app business. This webinar will reveal how to protect apps from harm without degrading the user experience. Lu Bolden, Chief Revenue Officer at Verimatrix will moderate. Panelist will include Pedro Fortuna, Co-Founder & CTO at Jscrambler and Neal Michie, Director Product Management at Verimatrix.
Defend and Protect: How Cybercriminals Are Hacking Healthcare Workflows & How to Stop Them
Thursday, July 9, 8:00am PT / 3:00pm GMT
Moderated by Adam Turinas, this panel session will explore how cybercriminals can cripple healthcare workflows. It will uncover how tele-health platforms, apps and devices can be hacked relatively easily, share examples of breaches and review the latest security techniques. The results of a security effectiveness test of the world’s top 20 healthcare apps will be shared during the session. The webinar will be moderated by Adam Turinas, CEO & Founder of HealthLaunchpad. Panelists include John Ulett, CIO of CentraState Healthcare System, John Hendricks, CTO of Huntzinger Management Group, Brian Lawrence, Director Solution Engineering at NowSecure and Asaf Ashkenazi, Chief Operating Officer at Verimatrix.
Churning It Around: How to Identify and Retain At-Risk Video and Internet Service Subscribers Using Data Stories
Thursday, July 9, 9:00am PT / 4:00pm GMT
This panel will explore how security vendors and systems integrators are working with operators to utilize the latest data harvesting & analytics tools to surface subscriber profitability stories. This can lead to actionable insights powerful enough to boost consumption rates, reduce churn and increase ARPU – all of which are especially critical in a climate of tight pocketbooks caused by COVID-19. Moderated by Sebastian Braun, Director Product Management at Verimatrix, this panel will feature Luc Bleylevens, Senior Product Director, Subscriber Retention Management at Cleeng, Daragh O Brien, CEO & Managing Director of Castlebridge and Derek Harrar, CEO of Zodiac.
Adapt or Die: The Content Distribution Business Model in Flux
Thursday, July 9, 11:30am PT / 6:30pm GMT
Speakers from Xperi (TiVo) and 3Vision come together for this insightful session on the impact of COVID-19 on the traditional Hollywood business and their audiences. Topics to be explored include what’s changing within the content distribution business model and why, the shifting power of content producers, trends in security technologies and integration methods and more. Moderated by Lu Bolden, Chief Revenue Officer at Verimatrix, this webinar will feature Nic Wilson, Head of Customer Success at TiVo and Jack Davison, EVP of 3Vision.
To learn more about the Verimatrix Summer Summit, or register to attend any of the sessions go to www.summit.verimatrix.com.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. To learn more, visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005500/en/
Contact information
Investor and media
Investor Relations
Richard Vacher Detournière
General Manager & Chief Financial Officer
+33 (0)4 42 905 905
finance@verimatrix.com
Contact Media
Kelly Foster
+1 619 224 1261
kfoster@verimatrix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom